Question 1

Has Martin Kankam received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $63,436,379 in general payments to Martin Kankam across 682 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Martin Kankam did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Martin Kankam come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Novo Nordisk AS	332	$23,965,088
Avanir Pharmaceuticals, Inc.	93	$8,547,500
Vertex	4	$7,492,081
Eli Lilly	2	$4,956,097
Merck	45	$4,672,203
Takeda Pharmaceuticals U.S.A., Inc.	12	$2,383,641
GSK	18	$1,612,163
Biogen	3	$1,351,826
Indivior Inc.	36	$1,250,808
Myovant Sciences GmbH	32	$1,244,048
Eiger Biopharmaceuticals, Inc.	16	$1,086,994
E.r. Squibb & Sons, L.L.C.	1	$1,018,102
Sage Therapeutics, LLC	10	$777,043
Pfizer	22	$719,606
Urovant Sciences Inc	24	$657,064
Amgen	3	$403,411
Amphastar Pharmaceuticals, Inc.	1	$376,796
MDD US Operations, LLC	11	$319,314
USWM, LLC	8	$218,564
Grifols Therapeutics LLC	4	$189,103
Emergent Biosolutions Inc.	2	$100,575
Novartis	2	$93,140
Alkermes, Inc.	1	$1,209

Martin Kankam

Payments from drug & device makers

Who reported the general payments

How this compares

Other internal medicine in Leavenworth